| Ytd | -13.55% | |
| 1y | -15.58% |
| Open | 6.03 | Prev Close | 6.06 | Low | 5.97 | High | 6.10 | Mkt Cap | 553.83M |
| Vol | 2.42K | Avg Vol | 93.84K | EPS | 0.07 | P/E | 86.57 | Forward P/E | 25.22 |
| Beta | 1.89 | Short Ratio | 21.22 | Inst. Own | 1.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 6.34 | 200-d Avg | 7.37 | 1yr Est | 0.00 |
GYRE News
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or
Newtown Square, Pennsylvania--(Newsfile Corp. - May 27, 2026) - Kaskela Law LLC is investigating Gyr
GYRE, FSUN and AKZOY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2026.
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or
Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.05 per share versus the Zacks Co
Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5
Post-closing combined company has revenue-producing commercial asset and a robust pipeline of produc
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (N
Gyre Therapeutics, Inc. (GYRE) came out with quarterly earnings of $0.04 per share, missing the Zack
Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range
Tenax Therapeutics (NASDAQ: TENX - Get Free Report) and Gyre Therapeutics (NASDAQ: GYRE - Get Free R
Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with reve
ImmunityBio (NASDAQ: IBRX - Get Free Report) and Gyre Therapeutics (NASDAQ: GYRE - Get Free Report)
Gyre Pharmaceuticals completed a Pre-NDA meeting with China's CDE, which agreed that the existing Ph
Gyre Therapeutics, Inc. (GYRE) came out with quarterly earnings of $0.06 per share, beating the Zack
Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025,
GYRE, DAR and CRLBF have been added to the Zacks Rank #5 (Strong Sell) List on October 17, 2025.
SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commer
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (Nasdaq: GYRE), an innovativ
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovati